A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel and Nintedanib for Resectable Non-Small Cell Lung Cancer

PURPOSE. Nintedanib enhances the activity of chemotherapy in metastatic NSCLC. In this phase I/II study, we assessed safety and efficacy of nintedanib plus neoadjuvant chemotherapy, using major pathologic response (MPR) as primary endpoint. EXPERIMENTAL DESIGN: Eligible patients had stage IB (≥4 cm)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Cascone, Tina, Sepesi, Boris, Lin, Heather Y., Kalhor, Neda, Parra, Edwin R., Jiang, Mei, Godoy, Myrna C. B., Zhang, Jianjun, Fossella, Frank V., Tsao, Anne, Lam, Vincent K., Lu, Charles, Mott, Frank E., Simon, George, Antonoff, Mara B., Mehran, Reza J., Rice, David C., Behrens, Carmen, Weissferdt, Annikka, Moran, Cesar, Vaporciyan, Ara A., Lee, J. Jack, Swisher, Stephen G., Gibbons, Don L., Wistuba, Ignacio I., William, William N., Heymach, John V.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7446232/
https://ncbi.nlm.nih.gov/pubmed/32193228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-4180
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados